{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:32:07Z","timestamp":1769848327127,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this study was to investigate the oncologic efficacy of combining docetaxel with androgen deprivation therapy (ADT) versus nonsteroidal antiandrogen (NSAA) with ADT in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) with focus on the effect of sequential therapy in a real-world clinical practice setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The records of 382 patients who harbored high-volume mHSPC, based on the CHAARTED criteria, and had received ADT with either docetaxel (<jats:italic>n<\/jats:italic>\u2009=\u200992) or NSAA (bicalutamide) (<jats:italic>n<\/jats:italic>\u2009=\u2009290) were retrospectively analyzed. The cohorts were matched by one-to-one propensity scores based on patient demographics. Overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), including time to castration-resistant prostate cancer (CRPC), and time to second-line progression (PFS2) were compared. 2nd-line PFS defined as the time from CRPC diagnosis to progression after second-line therapy was also compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After matching, a total of 170 patients were retained: 85 patients treated with docetaxel\u2009+\u2009ADT and 85 patients treated with NSAA\u2009+\u2009ADT. The median OS and CSS for docetaxel\u2009+\u2009ADT versus NSAA\u2009+\u2009ADT were not reached (NR) vs. 49\u00a0months (<jats:italic>p<\/jats:italic>\u2009=\u20090.02) and NR vs. 55\u00a0months (<jats:italic>p<\/jats:italic>\u2009=\u20090.02), respectively. Median time to CRPC and PFS2 in patients treated with docetaxel\u2009+\u2009ADT was significantly longer compared to those treated with NSAA (22 vs. 12\u00a0months; <jats:italic>p<\/jats:italic>\u2009=\u20090.003 and, NR vs. 28\u00a0months; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, respectively). There was no significant difference in 2nd-line PFS between the two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our analysis suggested that ADT with docetaxel significantly prolonged OS and CSS owing to a better time to CRPC and PFS2 in comparison to NSAA\u2009+\u2009ADT in high-volume mHSPC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-022-04030-2","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T09:02:33Z","timestamp":1653123753000},"page":"2051-2062","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7410-0712","authenticated-orcid":false,"given":"Takafumi","family":"Yanagisawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Hata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Enei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Nakazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Sakanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Iwatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahito","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideomi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Habuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikara","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"issue":"2","key":"4030_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","volume":"19","author":"E Schaeffer","year":"2021","unstructured":"Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H et al (2021) NCCN guidelines insights: prostate cancer, version 1202.1. J Natl Compr Canc Netw. 19(2):134\u201343. https:\/\/doi.org\/10.6004\/jnccn.2021.0008 (Epub 2021\/02\/06 PubMed PMID: 33545689)","journal-title":"J Natl Compr Canc Netw."},{"issue":"17","key":"4030_CR2","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1158\/1078-0432.CCR-10-0255","volume":"16","author":"M Yamaoka","year":"2010","unstructured":"Yamaoka M, Hara T, Kusaka M (2010) Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin Cancer Res 16(17):4319\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0255 (Epub 2010\/07\/22 PubMed PMID: 20647476)","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4030_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1503747 (Epub 2015\/08\/06 PubMed PMID: 26244877; PubMed Central PMCID: PMCPMC4562797)","journal-title":"N Engl J Med"},{"issue":"10024","key":"4030_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(15)01037-5 (Epub 2016\/01\/01 PubMed PMID: 26719232; PubMed Central PMCID: PMCPMC4800035)","journal-title":"Lancet"},{"issue":"2","key":"4030_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79(2):263\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.046 (Epub 2020\/10\/12 PubMed PMID: 33039206)","journal-title":"Eur Urol"},{"issue":"9214","key":"4030_CR6","first-page":"1491","volume":"355","author":"Maximum androgen blockade in advanced prostate cancer","year":"2000","unstructured":"Maximum androgen blockade in advanced prostate cancer (2000) An overview of the randomised trials. Prost Cancer Trialists\u2019 Collabo Group Lancet 355(9214):1491\u20131498 (Epub 2000\/05\/09 PubMed PMID: 10801170)","journal-title":"Prost Cancer Trialists' Collabo Group Lancet"},{"issue":"15","key":"4030_CR7","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","volume":"339","author":"MA Eisenberger","year":"1998","unstructured":"Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ et al (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339(15):1036\u201342. https:\/\/doi.org\/10.1056\/NEJM199810083391504 (Epub 1998\/10\/0 PubMed PMID: 9761805)","journal-title":"N Engl J Med"},{"key":"4030_CR8","doi-asserted-by":"publisher","first-page":"S660","DOI":"10.1016\/j.annonc.2021.08.1136.PubMedPMID:WOS:000700527701089","volume":"32","author":"PJ Goebell","year":"2021","unstructured":"Goebell PJ, Shah R, Raina R, Rege S, Chen SL, Lee VE et al (2021) Real-world treatment patterns in metastatic hormone-sensitive prostate cancer (mHSPC) patients in the US, Germany, France. China Japan Ann Oncol 32:S660\u2013S661. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1136.PubMedPMID:WOS:000700527701089","journal-title":"China Japan Ann Oncol"},{"issue":"2","key":"4030_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate canCER. N Engl J Med 381(2):121\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1903835 (Epub 2019\/06\/04 Epub 2019\/06\/04)","journal-title":"N Engl J Med"},{"issue":"12","key":"4030_CR10","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","volume":"30","author":"NW Clarke","year":"2019","unstructured":"Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G et al (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 30(12):1992\u20132003. https:\/\/doi.org\/10.1093\/annonc\/mdz396 (Epub 2019\/09\/29 PubMed PMID: 31560068; PubMed Central PMCID: PMCPMC6938598)","journal-title":"Ann Oncol"},{"issue":"11","key":"4030_CR11","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 36(11):1080\u20137. https:\/\/doi.org\/10.1200\/JCO.2017.75.3657 (Epub 2018\/02\/01 PubMed Central PMCID: PMCPMC5891129)","journal-title":"J Clin Oncol"},{"issue":"2","key":"4030_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026 (Epub 2008\/12\/23 PubMed PMID: 19097774)","journal-title":"Eur J Cancer"},{"issue":"1","key":"4030_CR13","first-page":"195","volume":"61","author":"MS Soloway","year":"1988","unstructured":"Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer-Am Cancer Soc 61(1):195\u2013202 (Epub 1988\/01\/01)","journal-title":"Cancer-Am Cancer Soc"},{"issue":"9","key":"4030_CR14","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.neo.2015.09.001","volume":"17","author":"B Oronsky","year":"2015","unstructured":"Oronsky B, Carter CA, Reid TR, Scicinski J, Oronsky A, Lybeck M et al (2015) Confirmatory trials in the evaluation of anticancer medicinal products in man\u2013PFS2: a measure of therapeutic action-at-a-distance. Neoplasia 17(9):716\u201322. https:\/\/doi.org\/10.1016\/j.neo.2015.09.001 (Epub 2015\/10\/18 PubMed PMID: 26476079; PubMed Central PMCID: PMCPMC4611069)","journal-title":"Neoplasia"},{"issue":"2","key":"4030_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10(2):150\u201361. https:\/\/doi.org\/10.1002\/pst.433 (PubMed PMID: 20925139; PubMed Central PMCID: PMCPMC3120982)","journal-title":"Pharm Stat"},{"issue":"16","key":"4030_CR16","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1002\/sim.5705.PubMedPMID:23239115;PubMedCentralPMCID:PMCPMC3747460","volume":"32","author":"PC Austin","year":"2013","unstructured":"Austin PC (2013) The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med 32(16):2837\u20132849. https:\/\/doi.org\/10.1002\/sim.5705.PubMedPMID:23239115;PubMedCentralPMCID:PMCPMC3747460","journal-title":"Stat Med"},{"issue":"2","key":"4030_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F et al (2016) Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 70(2):256\u201362. https:\/\/doi.org\/10.1016\/j.eururo.2015.11.005 (Epub 2015\/11\/28. doi: 10.1016\/j.eururo.2015.11.005. PubMed PMID: 26610858)","journal-title":"Eur Urol"},{"issue":"1","key":"4030_CR18","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/j.clgc.2018.10.010","volume":"17","author":"JYC Teoh","year":"2019","unstructured":"Teoh JYC, Poon DMC, Lam D, Chan T, Chan MFT, Lee EKC et al (2019) A territory-wide, multicenter, age- and prostate-specific antigen-matched study comparing chemohormonal therapy and hormonal therapy alone in chinese men with metastatic hormone-sensitive prostate cancer. Clin Genitourin Cancer 17(1):e203\u2013e8. https:\/\/doi.org\/10.1016\/j.clgc.2018.10.010 (Epub 2018\/11\/21 PubMed PMID: 30454968)","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"4030_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.clgc.2017.12.012","volume":"16","author":"E Francini","year":"2018","unstructured":"Francini E, Yip S, Ahmed S, Li H, Ardolino L, Evan CP et al (2018) Clinical outcomes of first-line abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer after androgen deprivation therapy + docetaxel or ADT alone for metastatic hormone-sensitive prostate cancer. Clin Genitourin Cancer 16(2):130\u20134. https:\/\/doi.org\/10.1016\/j.clgc.2017.12.012","journal-title":"Clin Genitourin Cancer"},{"key":"4030_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.06.018","author":"I Tsaur","year":"2020","unstructured":"Tsaur I, Heidegger I, van den Bergh RCN, Bektic J, Borgmann H, Foti S et al (2020) Treatment of metastasized prostate cancer beyond progression after upfront docetaxel-a real-world data assessment. Eur Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2020.06.018 (Epub 2020\/07\/13 PubMed PMID: 32653263)","journal-title":"Eur Urol Focus"},{"issue":"4","key":"4030_CR21","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41391-020-0231-5","volume":"23","author":"A Martini","year":"2020","unstructured":"Martini A, Pfail J, Montorsi F, Galsky MD, Oh WK (2020) Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial. Prostate Cancer Prostatic Dis 23(4):638\u201345. https:\/\/doi.org\/10.1038\/s41391-020-0231-5","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"4030_CR22","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00345-018-2236-4","volume":"36","author":"S Frees","year":"2018","unstructured":"Frees S, Akamatsu S, Bidnur S, Khalaf D, Chavez-Munoz C, Struss W et al (2018) The impact of time to metastasis on overall survival in patients with prostate cancer. World J Urol 36(7):1039\u201346. https:\/\/doi.org\/10.1007\/s00345-018-2236-4 (PubMed PMID: 29488095)","journal-title":"World J Urol"},{"issue":"3","key":"4030_CR23","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.21873\/anticanres.13253","volume":"39","author":"H Miyake","year":"2019","unstructured":"Miyake H, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T et al (2019) Prognostic significance of time to castration resistance in patients with metastatic castration-sensitive prostate cancer. Anticancer Res 39(3):1391\u20136. https:\/\/doi.org\/10.21873\/anticanres.13253 (PubMed PMID: 30842173)","journal-title":"Anticancer Res"},{"issue":"7","key":"4030_CR24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/iju.14258","volume":"27","author":"S Hatakeyama","year":"2020","unstructured":"Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S et al (2020) Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: a multicenter retrospective study. Int J Urol 27(7):610\u20137. https:\/\/doi.org\/10.1111\/iju.14258 (Epub 2020\/05\/18PubMed PMID: 32418347)","journal-title":"Int J Urol"},{"issue":"4","key":"4030_CR25","doi-asserted-by":"publisher","first-page":"e402","DOI":"10.1016\/j.clgc.2019.12.002","volume":"18","author":"K Mori","year":"2020","unstructured":"Mori K, Janisch F, Mostafaei H, Lysenko I, Karakiewicz PI, Enikeev DV et al (2020) Prognostic value of hemoglobin in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Clin Genitourin Cancer 18(4):e402\u2013e9. https:\/\/doi.org\/10.1016\/j.clgc.2019.12.002 (PubMed PMID: 32007439)","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"4030_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10147-019-01578-9","volume":"25","author":"K Mori","year":"2020","unstructured":"Mori K, Janisch F, Parizi MK, Mostafaei H, Lysenko I, Enikeev DV et al (2020) Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis. Int J Clin Oncol 25(2):247\u201357. https:\/\/doi.org\/10.1007\/s10147-019-01578-9 (PubMed PMID: 31768692; PubMed Central PMCID: PMCPMC6989419)","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"4030_CR27","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/pros.23373","volume":"77","author":"K Mori","year":"2017","unstructured":"Mori K, Kimura T, Onuma H, Kimura S, Yamamoto T, Sasaki H et al (2017) Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer. Prostate 77(10):1144\u201350. https:\/\/doi.org\/10.1002\/pros.23373 (PubMed PMID: 28557065)","journal-title":"Prostate"},{"key":"4030_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24243","author":"T Yanagisawa","year":"2021","unstructured":"Yanagisawa T, Kimura T, Mori K, Suzuki H, Sano T, Otsuka T et al (2021) Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer. Prostate. https:\/\/doi.org\/10.1002\/pros.24243 (PubMed PMID: 34559410)","journal-title":"Prostate"},{"issue":"5","key":"4030_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jjco\/hyn029","volume":"38","author":"S Naito","year":"2008","unstructured":"Naito S, Tsukamoto T, Koga H, Harabayashi T, Sumiyoshi Y, Hoshi S et al (2008) Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in Japan. Jpn J Clin Oncol 38(5):365\u201372. https:\/\/doi.org\/10.1093\/jjco\/hyn029 (Epub 2008\/04\/18 PubMed PMID: 18417502)","journal-title":"Jpn J Clin Oncol"},{"key":"4030_CR30","doi-asserted-by":"publisher","first-page":"S1300","DOI":"10.1016\/j.annonc.2021.08.2101.PubMedPMID:WOS:000700527703500","volume":"32","author":"AJ Armstrong","year":"2021","unstructured":"Armstrong AJ, Iguchi T, Azad AA, Szmulewitz RZ, Holzbeierlein J, Villers A et al (2021) Final overall survival (OS) analysis from ARCHES: a phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). Ann Oncol 32:S1300\u2013S1301. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.2101.PubMedPMID:WOS:000700527703500","journal-title":"Ann Oncol"},{"issue":"20","key":"4030_CR31","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, Chung BH, de Santana P, Gomes AJ, Given R et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 39(20):2294\u2013303. https:\/\/doi.org\/10.1200\/JCO.20.03488 (Epub 2021\/04\/30 PubMed PMID: 33914595)","journal-title":"J Clin Oncol"},{"issue":"5","key":"4030_CR32","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20(5):686\u2013700. https:\/\/doi.org\/10.1016\/S1470-2045(19)30082-8 (Epub 2019\/04\/17 PubMed PMID: 30987939)","journal-title":"Lancet Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04030-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-022-04030-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04030-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T11:25:36Z","timestamp":1691666736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-022-04030-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["4030"],"URL":"https:\/\/doi.org\/10.1007\/s00345-022-04030-2","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,21]]},"assertion":[{"value":"29 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u30fbTakahiro Kimura is a paid consultant\/advisor of Astellas, Bayer, Janssen, and Sanofi. Shintaro Narita received honoraria from Janssen Pharmaceutical K.K., Bayer AG. Dr., AstraZeneca K.K., Takeda Pharmaceutical Company Ltd., Sanofi S.A., Astellas Pharma Inc., and grants for research from Novartis Pharmaceuticals. Shingo Hatakeyama received honoraria from Janssen Pharmaceutical K.K. and Pfizer Inc. Department of Advanced Blood Purification Therapy is an endowment department, supported by a grant from NIPRO Corporation. Tomonori Habuchi received honoraria from Janssen Pharmaceutical K.K., Takeda Pharmaceutical Company Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Ltd., AstraZeneca K.K., Sanofi S.A., and Bayer AG. Chikara Ohyama received honoraria from Astellas Pharma Inc., NIPPON SHINYAKU Company Ltd., AstraZeneca K.K., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Company Ltd., Novartis Pharma K.K., ONO Pharmaceutical Company Ltd., Chugai Pharmaceutical Company Ltd., Sanofi S.A., Bayer AG., Pfizer Inc., Bristol Myers Squibb, Otsuka Pharmaceutical Company Ltd., KISSEI Pharmaceutical Company Ltd., Kyowa Kirin Company Ltd., Daiichi Sankyo Company Ltd., KANEKA Corporation, and Nipro Corporation. Shahrokh F. Shariat received as follows: Honoraria: Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Roche, and Takeda Consulting or Advisory Role: Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Pierre Fabre, Roche, and Takeda Speakers Bureau: Astellas, Astra Zeneca, Bayer, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Richard Wolf, Roche, and Takeda Shin Egawa is a paid consultant\/advisor of Takeda, Astellas, AstraZeneca, Sanofi, Janssen, and Pfizer. The other authors declare no conflicts of interest associated with this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}